Bionik Laboratories Raises $6.2 Million

Bionik Laboratories is an innovative medical-robotics company that develops healthcare solutions for patients with restricted physical mobility.

TORONTO, Feb. 27, 2015 -- Bionik Laboratories Corp. (OTC:DWTPD), a Delaware corporation (the "Company"), announced today that it acquired Bionik Laboratories, Inc., a Toronto corporation ("Bionik Laboratories"), and completed the sale to qualified accredited investors of units consisting of its common stock and warrants for aggregate gross proceeds of approximately $6.2 million. Shares of the Company's common stock will continue to be quoted on the OTC Markets under the symbol "DWTPD" until FINRA's approval of the ticker "BNKL."


Bionik Laboratories is an innovative medical-robotics company that develops healthcare solutions for patients with restricted physical mobility.

Peter Bloch, CEO of Bionik Laboratories, stated, "Our team at Bionik Labs is focused and dedicated to deploying cutting edge solutions that will assist mobility impaired people. As a company, we are committed to improving the lives of hundreds of thousands of people and we are excited to be in the forefront of this new and developing technology."

The securities sold in the private placement have not been registered under the Securities Act of 1933 and may not be offered, sold or resold absent registration or an applicable exemption from registration under such Act.

The Company intends to file a Current Report on Form 8-K with the Securities and Exchange Commission with more detailed information in accordance with the SEC rules.

About Bionik Laboratories
Founded in 2010 by Michal Prywata and Thiago Caires, Bionik Laboratories (http://www.Bioniklabs.com), a medical device and robotics company, core focus is robotic exoskeleton technology for users with mobility impairments. The technology provides the ability for users to rehabilitate effectively by being able to actually walk with the help of the technology. Bionik Laboratories has researched, developed and tested its primary product, The ARKE, an exoskeleton device that allows paraplegics and other mobility impaired individuals to stand up, walk and rehabilitate in a more effective way than current manual rehabilitation methods.

Featured Product

TUV Rheinland Robot Integrator Program

TUV Rheinland Robot Integrator Program

The industry's first comprehensive Robot Integrator Program saves robot integrators significant time and cost investments by allowing them to mark each cell compliant with ANSI/RIA R15.06 with the TUV Rheinland Mark. As opposed to a traditional certification or an on-site field labeling, TÜV Rheinland's Robot Integrator Program certifies the knowledge and skill-set of robot integrators in addition to testing robotic cells and processes against ANSI/RIA R15.06. This reduces the need for frequent onsite or off site testing and allows manufacturers to apply a single TÜV Rheinland label to multiple cells. The Robot Integrator Program individually assesses a robot integrator's understanding of the ANSI/RIA R15.06 standard along with the ability to consistently produce compliant robot cells. Following the requirements and procedures of the new program will enable robot integrators to produce individually compliant robotic cells under one serialized TÜV Rheinland Mark, which meets the national electric code and allows acceptance by Authorities Having Jurisdiction (AHJ) and end users.